Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer-Reference-Cited by-同舟云学术

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

Published:2020-12-11 Issue:6522 Volume:370 Page:1328-1334
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Krishna Sri¹^ORCID,Lowery Frank J.¹^ORCID,Copeland Amy R.¹^ORCID,Bahadiroglu Erol²^ORCID,Mukherjee Ratnadeep²^ORCID,Jia Li³^ORCID,Anibal James T.²,Sachs Abraham¹,Adebola Serifat O.²,Gurusamy Devikala¹^ORCID,Yu Zhiya¹^ORCID,Hill Victoria¹^ORCID,Gartner Jared J.¹^ORCID,Li Yong F.¹,Parkhurst Maria¹,Paria Biman¹^ORCID,Kvistborg Pia⁴,Kelly Michael C.⁵^ORCID,Goff Stephanie L.¹^ORCID,Altan-Bonnet Grégoire²^ORCID,Robbins Paul F.¹^ORCID,Rosenberg Steven A.¹^ORCID

Affiliation:

1. Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

2. Immunodynamics Group, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

3. National Institutes of Health Library, National Institutes of Health, Bethesda, MD 20892, USA.

4. Division of Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

5. Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory, Bethesda, MD 20892, USA.

Abstract

Stem-like T cells mediate response Adoptive cell transfer (ACT) is a type of immunotherapy that uses a patient's own T lymphocytes to recognize and attack cancer. ACT has been effective in treating certain patients with metastatic melanoma and is being applied to treat some epithelial cancers. Krishna et al. investigated why some cancer patients respond to ACT, whereas others do not. They identified a population of CD8 + T cells that had stem-like surface markers that were associated with effective tumor cell killing and favorable response of melanoma patients to ACT. Only a small subset of T cells specific against tumor mutations were found in this stem-like state, whereas most mutation-reactive T cells were terminally differentiated. These findings could be of value in improving cancer immunotherapy outcomes. Science , this issue p. 1328

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference62 articles.

1. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

2. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

3. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

4. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

5. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Cited by 337 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alginate-based artificial antigen presenting cells expand functional CD8+ T cells with memory characteristics for adoptive cell therapy;Biomaterials;2025-02

2. Powerful microscopy technologies decode spatially organized cellular networks that drive response to immunotherapy in humans;Current Opinion in Immunology;2024-12

3. Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation;Scientific Reports;2024-09-12

4. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09

5. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09